Symberix
Gregory J. Mossinghoff, Chief Business Officer, has over 25 years of domestic and international bio-pharmaceutical industry experience. Starting with a 10-year big-pharma foundation at Roche and Glaxo, he has subsequent experience in numerous emerging bio-pharmaceutical companies in various roles such as Board Member, President, CEO, CBO, CFO, Principal Financial Officer and Co-Founder. He has co-led multiple venture financing rounds and two successful biotech IPOs: G1 Therapeutics and Inspire Pharmaceuticals, which was subsequently acquired by Merck & Co. In total he has participated in raising more than $450m in public and private equity capital and has negotiated and closed more than twenty important licensing/partnership agreements. Mr. Mossinghoff has a BA in Economics from the University of Virginia and an MBA in Financial Management and Analysis from George Mason University.
This person is not in any offices
Symberix
Symberix, an early-stage spin-out of the University of North Carolina at Chapel Hill, aims to improve human health by pioneering the development of symbiotic drugs that work by controlling bacteria without killing them.